Wednesday, July 8, 2026

pharma · Chronic Lymphocytic Leukemia · Relapsing Multiple Sclerosis · TGTX

TG THERAPEUTICS

TG THERAPEUTICS is a pharma organization headquartered in Morrisville, USA. It trades on NYSE under ticker TGTX. Primary therapeutic focus areas include Chronic Lymphocytic Leukemia, Relapsing Multiple Sclerosis, Hodgkin

3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US HQ
2011 Founded
521 Employees
Public company Type
TGTX · NYSE Ticker
Company details
Status
Public
HQ
3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US
Founded
2011
Employees
521
Programs
39
Drugs
23
Patents
7

Quick answer

TG THERAPEUTICS is a pharma organization headquartered in Morrisville, USA. It trades on NYSE under ticker TGTX. Primary therapeutic focus areas include Chronic Lymphocytic Leukemia, Relapsing Multiple Sclerosis, Hodgkin's Lymphoma, Follicular Lymphoma, multiple sclerosis. NovaPharmaNews links 39 clinical program(s), 1 drug profile(s), and 7 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (15), phase 2 (13), phase 3 (9).

Company snapshot

TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) and from several regulatory agencies outside of the U.S for its therapy as a treatment for rela

  • 1 approved product(s) across US/EU regulatory metadata.
  • 39 active pipeline program(s) linked via ClinicalTrials.gov.
  • 7 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for TG THERAPEUTICS. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for TG THERAPEUTICS.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 48 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for TG THERAPEUTICS.

  1. Clinical update

    TG1101-RMS-SC101 — Phase 1

  2. Clinical update

    TG1101-RMS401 — Phase 3

  3. Clinical update

    TG1101-RMS-PED304 — Phase 3

  4. Clinical update

    ublituximab — Phase 3

  5. Clinical update

    Ublituximab, ublituximab — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is TG THERAPEUTICS?

    TG THERAPEUTICS is a pharma organization headquartered in Morrisville, USA. It trades on NYSE under ticker TGTX. Primary therapeutic focus areas include Chronic Lymphocytic Leukemia, Relapsing Multiple Sclerosis, Hodgkin's Lymphoma, Follicular Lymphoma, multiple sclerosis. NovaPh

  • Is TG THERAPEUTICS publicly traded?

    Yes. TG THERAPEUTICS is listed with ticker TGTX on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does TG THERAPEUTICS develop or market?

    We link 23 drug profile(s) where TG THERAPEUTICS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/tg-therapeutics-inc#company-drugs.

  • What are the latest developments for TG THERAPEUTICS?

    In the last 12 months our linked public records show 39 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does TG THERAPEUTICS focus on?

    TG THERAPEUTICS focuses on Chronic Lymphocytic Leukemia, Relapsing Multiple Sclerosis, Hodgkin's Lymphoma based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
47
Neurology
4
Oncology
4
Immunology
3